As stated in yesterdays portfolio update I sold off part of my position in Enzymatica. Today I have bought back the majority of these shares below 10 sek. Analyst house Erik Penser has lowered the target price to 16-17 SEK which is still quite appealing compared to the current share price of around 10 SEK ( at time of publication).
The long term investment case for Enzymatica remains the same, I have very good personal experience from the product and it also seems that parts of the planned capital injection will go towards more studies to further strengthen the already strong proof of concept. Furthermore there was another article just released (lunchtime CET 23/3 2021) with an interview of Enzymaticas chairman Bengt Baron. This interview further strengthens my long term investment case as he seems confident that the current drawback in sales due to covid will wear off during this fall 2021.
Lastly but not least the interview also states Enzymatica is currently negotiating for even more markets to launch its products in which may balance up the drop in sales due to improved hygienic measures because of COVID-19.
Side note With Nuvve Corp
Sidenote to todays post is that I plan on adding to my position in $NBAC which today will start trading as Nuvve corp. Nuvve corp is my only electric charge company in the portfolio and is the leader of vehicle to grid solutions that stabilize the power grid. With millions of electric cars expecting to be sold in the coming years this company is positioned for extremely strong growth and with a very strong IP portfolio. The vehicle to grid market is expected to be worth $ 17 Billion USD by 2027.
I own shares in these companies personally and this is not to be considered financial advise, always do your own research!
Don’t forget to subscribe to this blog by pressing “follow” or going to the main page furthest down and sign up to receive news update as soon as they’re published!